Institution: Universiti Teknologi MARA (UiTM)

Sign In

|
My Tools

|
Contact Us

|
Help

Search all journals

Browse Journals

Skip to main page content

Home OnlineFirst All Issues Subscribe RSS Email Alerts

Search this journal

Advanced Journal Search

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone
1. 2. 3. 4. Y. W. Francis Lam, PharmD Cara L. Alfaro, PharmD Larry Ereshefsky, PharmD Michael Miller, MD 1. From the Departments of Pharmacology (Dr. Lam, Dr. Alfaro, Dr. Ereshefsky), Medicine (Dr. Lam), and Psychiatry (Dr. Ereshefsky, Dr. Miller), University of Texas Health Science Center at San Antonio, Texas, and the College of Pharmacy, University of Texas at Austin, Texas (Dr. Lam, Dr. Alfaro, Dr. Ereshefsky). 1. Dr. Larry Ereshefsky, Pharmacotherapy Division, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-6220. Abstract

The objective of this study was to investigate pharmacokinetic and pharmacodynamic interactions between midazolam and fluoxetine, fluvoxamine, nefazodone, and ketoconazole. Forty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days; fluvoxamine titrated to a daily dose of 200 mg; nefazodone titrated to a daily dose of 400 mg; or ketoconazole 200 mg per day. All 40 subjects received oral midazolam solution before and after the 12-day study drug regimen. Blood samples for determination of midazolam concentrations were drawn for 24 hours after each midazolam dose and used for the calculation of pharmacokinetic parameters. The effects of the study drugs on midazolam pharmacodynamics were assessed using the symbol digit modalities test (SDMT). The mean area under the curve (AUC) for midazolam was increased 771.9% by ketoconazole and 444.0% by nefazodone administration. However, there was no significant change in midazolam AUC as a result of fluoxetine (13.4% decrease) and a statistical trend for fluvoxamine (66.1% increase) administration. Pharmacodynamic data are consistent with pharmacokinetic data indicating that nefazodone and ketoconazole resulted in significant increases in midazolam-related cognition impairment. The significant impairment in subjects' cognitive function reflects the changes in midazolam clearance after treatment with ketoconazole and nefazodone. These results suggest that caution with the use of midazolam is warranted with potent CYP3A4 inhibitors.
Cytochrome P450 3A

selective serotonin reuptake inhibitors nefazodone midazolam

Received September 26, 2002. Accepted August 28, 2003.

Articles citing this article

Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation ConditionsDrug Metab. Dispos. April 1, 2012 40: 706-716 Abstract Full Text Full Text (PDF) Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human PlasmaDrug Metab. Dispos. April 1, 2011 39: 591-602

o o o

o o o

Abstract Full Text Full Text (PDF) Does the Long Plasma Half-Life of 4{beta}-Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric?J Clin Pharmacol November 1, 2010 50: 1330-1338 Abstract Full Text Full Text (PDF) Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A InhibitorsDrug Metab. Dispos. July 1, 2010 38: 10941104 Abstract Full Text Full Text (PDF) Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N-OxideJ Clin Pharmacol November 1, 2008 48: 1339-1349 Abstract Full Text Full Text (PDF) Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in HumansDrug Metab. Dispos. May 1, 2008 36: 851-862 Abstract Full Text Full Text (PDF) Simultaneous Measurement of In Vivo P-glycoprotein and Cytochrome P450 3A Activities.J Clin Pharmacol November 1, 2006 46: 1313-1319 Abstract Full Text Full Text (PDF) STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLEDrug Metab. Dispos. July 1, 2006 34: 12081219 Abstract Full Text Full Text (PDF)
Previous | Next Article Table of Contents

o o o

o o o

o o o

o o o o o o

o o o

This Article
1. doi: 10.1177/0091270003259216J Clin Pharmacol November 2003 vol. 43 no. 11 1274-1282

1. 2. 3. 1. 2. 3. 4. 5. 6. 7. 8. 1. 2. 3. 1. 2. 3. 1. 2. 3. 4.

AbstractFree Full TextFree to you Full Text (PDF)

-Services

Free to you

Email this article to a colleague Alert me when this article is cited Alert me if a correction is posted Similar articles in this journal Similar articles in PubMed Download to citation manager Request Permissions Request Reprints
-Citing Articles

View citing article information Citing articles via Web of Science (43) Citing articles via Google Scholar
-Google Scholar

Articles by Lam, Y. W. F. Articles by Miller, M. Search for related content

-PubMed

PubMed citation Articles by Lam, Y. W. F. Articles by Miller, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB FLUOXETINE KETOCONAZOLE MIDAZOLAM HYDROCHLORIDE
-Share

o o
1.

o o o o o o o o o o o o
1.

What's this?

This Article
doi: 10.1177/0091270003259216J Clin Pharmacol November 2003 vol. 43no. 11 1274-1282

1.

AbstractFree

2. 3.

Full TextFree to you Full Text (PDF) 1. Free to you

Current Issue
May 2012, 52 (5)

1.

Alert me to new issues of The Journal of Clinical Pharmacology

1. 2. 3. 4. 5.

Submit a Manuscript Free Sample Copy Email Alerts RSS feed PDA Link

+More

about this journal

Other journals by the ACCP

Clinical Pharmacology in Drug Development

2. 3.

1. American College of Clinical Pharmacology